4,6-二氯-1-苯基-1氢-吡唑[3,4-d]并嘧啶 | 99971-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4,6-二氯-1-苯基-1氢-吡唑[3,4-d]并嘧啶
• 中文别名: 4,6-二氯-1-苯基-1氢-吡唑[3,4-D]并嘧啶；4,6-二氯-1-苯基-1H-吡唑并[3,4-d]嘧啶
• 英文名称: 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 4,6-dichloro-1-phenylpyrazolo[3,4-d]pyrimidine
• CAS: 99971-84-3
• 化学式: C₁₁H₆Cl₂N₄
• 分子量: 265.101
• InChiKey: TVNFAHSWOCLZGO-UHFFFAOYSA-N

物化性质

• 沸点：
  341.4±42.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,6-二氯-1-苯基-1氢-吡唑[3,4-d]并嘧啶 在 氯化亚砜 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 28.0h， 生成 (2R-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-chloro-3H-imidazo<1,2-c>pyrazolo<4,3-e>pyrimidine
  参考文献：
  名称：

  Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors

  摘要：

  Two modes of tethering a chiral (phenylisopropyl)amino substituent in pyrazolo[3,4-d]pyrimidines and purines have been explored. One mode gave (S)-2,7-dihydro-7-phenyl-2-(phenylmethyl)-5-propoxy-3H-imidazo[1,2-c]pyrazolo-[4,3-e]pyrimidine (12a) and its corresponding R-enantiomer 12b, which were selective for A2 and A1 adenosine receptors, respectively. The corresponding diimidazo[1,2-c:4',5'-e]pyrimidines 12e and 12f were analogously selective. This is the first example where a single chiral recognition unit provides enantiomers with opposite selectivities for adenosine receptors. The second mode gave (2S-trans)-2,7-dihydro-2-methyl-3,7-diphenyl-5-propoxy-3H-imidazo[1,2-c]-pyrazolo[4,3-e]pyrimidine (12c) and its corresponding R-enantiomer 12d. Compounds 12c and 12d were significantly less potent than 12a and 12b at A1 receptors, and were nonselective.

  DOI：

  10.1021/jm00095a024
• 作为产物：
  描述：

  5-氨基-1-苯基吡唑-4-甲酰胺 在 五氯化磷 、 三氯氧磷 作用下， 反应 5.0h， 生成 4,6-二氯-1-苯基-1氢-吡唑[3,4-d]并嘧啶
  参考文献：
  名称：

  [EN] 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES
  [FR] COMPOSÉS BICYCLIQUES FUSIONNÉS EN 6-6 OU 5-6 COMPRENANT UN CYCLE PYRI(MI)DINE UTILES DANS LE TRAITEMENT DE MALADIES INFECTIEUSES

  摘要：

  The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein : Ar1is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is -CH-, -S-, -NR5or -N-, Y is -CH-, -NR5-S- or -NR6-CH2-, T is -CH- and Q is -CH- or T is -N- and Q is -CR10- or -N-, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5or R6, contains a group -NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

  公开号：

  WO2022129376A1

文献信息

• [EN] AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS D'AZOLOPYRIDINE ET D'AZOLOPYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2012030924A1

  公开（公告）日：2012-03-08

  Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗JAK激酶介导疾病的咪唑吡啶和咪唑吡啶化合物，包括JAK2激酶、JAK3激酶或TYK2激酶介导的疾病。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20150038546A1

  公开（公告）日：2015-02-05

  The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.

  本发明提供了钙感应受体调节剂（CaSR）。特别是，本发明的化合物可用于治疗、管理和/或减轻与钙感应受体（CaSR）调节相关的疾病、障碍、综合征和/或症状。本发明还提供了其药物组合物，以及用于治疗、管理和/或减轻与CaSR调节相关的疾病、障碍、综合征和/或症状的方法。本发明还涉及用于制备本发明化合物的过程。
• Discovery of 4-Morpholino-6-aryl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the 6-Aryl Substituent
  作者：Jeroen C. Verheijen、David J. Richard、Kevin Curran、Joshua Kaplan、Mark Lefever、Pawel Nowak、David J. Malwitz、Natasja Brooijmans、Lourdes Toral-Barza、Wei-Guo Zhang、Judy Lucas、Irwin Hollander、Semiramis Ayral-Kaloustian、Tarek S. Mansour、Ker Yu、Arie Zask

  DOI：10.1021/jm9013828

  日期：2009.12.24

  6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC50 against mTOR and greater than 1000-fold selectivity over PI3K-α. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds

  设计和合成了一系列4-吗啉代-6-芳基-1 H-吡唑并[3,4- d ]嘧啶，它们是雷帕霉素（mTOR）哺乳动物靶标的有效和选择性抑制剂。优化6-芳基取代基导致发现带有6-脲基苯基的抑制剂，这是第一个报道的具有亚纳摩尔抑制浓度的mTOR活性位点抑制剂。本文提供的数据表明，6-芳基脲基苯基取代基可产生有效的mTOR和磷脂酰肌醇3-激酶α（PI3K-α）混合抑制剂，而6-烷基脲基苯基附肢则具有高度选择性的mTOR抑制剂。6-烷基脲基苯基与1-氨基甲酰基哌啶取代的组合产生具有亚纳摩尔级IC 50的化合物对mTOR的抗性和对PI3K-α的选择性大于1000倍。另外，基于结构的药物设计导致制备了几种6-芳基脲基苯基-1H-吡唑并[3，4- d ]嘧啶，其在芳基脲基部分的4-位被水溶性基团取代。这些化合物将有效的mTOR抑制（IC 50 <1 nM）与细胞增殖试验（IC 50 <1 nM）中前所未有的活性结合在一起。
• Selective adenosine receptor agents
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05256650A1

  公开（公告）日：1993-10-26

  Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.

  抗腺苷类似物在腺苷受体上具有选择性作用，并通常作为腺苷拮抗剂。从体外研究中已知，由于这种选择性，可以区分特定的生理效应，并且体外腺苷受体活性与体内腺苷受体活性相关。根据本公开的化合物的选择性结合活性可以制备该类化合物的药物制剂，这将增强某些生理效应，同时减少其他效应，例如降低血压而不降低心率。
• [EN] PYRAZOLO-PYRIMIDINE ANILINE COMPOUNDS<br/>[FR] COMPOSES DE PYRAZOLO-PYRIMIDINE ANILINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099820A1

  公开（公告）日：2003-12-04

  Compounds having the formula (I), where all substituents are as defined herein, and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors.

  具有式(I)的化合物，其中所有取代基如本文所定义，并且其药用可接受的盐、前药和溶剂化合物对于作为激酶抑制剂是有用的。